ZA899058B - Treatment of obesity - Google Patents

Treatment of obesity

Info

Publication number
ZA899058B
ZA899058B ZA899058A ZA899058A ZA899058B ZA 899058 B ZA899058 B ZA 899058B ZA 899058 A ZA899058 A ZA 899058A ZA 899058 A ZA899058 A ZA 899058A ZA 899058 B ZA899058 B ZA 899058B
Authority
ZA
South Africa
Prior art keywords
obesity
treatment
Prior art date
Application number
ZA899058A
Other languages
English (en)
Inventor
Monte Lee Scheinbaum
Lee Scheinbaum Monte
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA899058(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of ZA899058B publication Critical patent/ZA899058B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA899058A 1988-11-29 1989-11-28 Treatment of obesity ZA899058B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-29 1988-11-29

Publications (1)

Publication Number Publication Date
ZA899058B true ZA899058B (en) 1990-08-29

Family

ID=23060006

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA899058A ZA899058B (en) 1988-11-29 1989-11-28 Treatment of obesity

Country Status (16)

Country Link
US (1) US5436272A (ko)
EP (1) EP0397831B1 (ko)
JP (1) JPH06102622B2 (ko)
KR (1) KR0164435B1 (ko)
AU (1) AU633529B2 (ko)
CA (1) CA2003524C (ko)
DE (2) DE19975039I2 (ko)
DK (1) DK175587B1 (ko)
HK (1) HK1006002A1 (ko)
IE (1) IE61928B1 (ko)
IL (1) IL92406A (ko)
LU (1) LU90866I2 (ko)
NL (1) NL300066I2 (ko)
PH (1) PH26677A (ko)
WO (1) WO1990006110A1 (ko)
ZA (1) ZA899058B (ko)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
IL145240A (en) * 1999-03-19 2007-02-11 Abbott Gmbh & Co Kg Compound and its use in the treatment of eating disorders
JP2002539250A (ja) 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 肺高血圧症の治療
MXPA01009461A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Tratamiento de osteoartritis.
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
TR200102694T2 (tr) * 1999-03-19 2002-04-22 Knoll Gmbh Hamilelik sonrası kilo kaybı.
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
MXPA01009462A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de calculos biliares.
AU3895400A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
SK13352001A3 (sk) * 1999-03-19 2002-03-05 Knoll Gmbh Použitie zlúčeniny na výrobu liečiva na kontrolu prírastku hmotnosti spojeného s terapeutickými liečivami
BR0009080A (pt) * 1999-03-19 2002-02-13 Knoll Gmbh Método de tratamento da apnéia do sono
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
CA2478183C (en) * 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
KR100830002B1 (ko) 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
NZ574710A (en) 2006-09-07 2012-02-24 Nycomed Gmbh Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus
BRPI0716952A2 (pt) * 2006-09-15 2013-10-29 Reviva Pharmaceuticals Inc Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
AP2009005026A0 (en) * 2007-04-09 2009-12-31 Scidose Llc Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CA2690004C (en) 2007-06-04 2018-01-23 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
WO2010065889A2 (en) * 2008-12-06 2010-06-10 Auspex Pharmaceutical Cyclobutanemethanamine inhibitors of monomine reuptake
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR20160094956A (ko) 2013-11-05 2016-08-10 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 당뇨병 및 당뇨병으로부터 발생하는 합병증 질환의 치료를 위한 화합물
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
KR0164435B1 (ko) 1999-01-15
IL92406A (en) 1995-07-31
PH26677A (en) 1992-09-15
DK177690D0 (da) 1990-07-26
DE68909219T2 (de) 1994-01-13
EP0397831A1 (en) 1990-11-22
JPH02503682A (ja) 1990-11-01
DE68909219D1 (de) 1993-10-21
AU633529B2 (en) 1993-02-04
CA2003524A1 (en) 1990-05-29
IE893690L (en) 1990-05-29
HK1006002A1 (en) 1999-02-05
AU4620789A (en) 1990-06-26
EP0397831B1 (en) 1993-09-15
WO1990006110A1 (en) 1990-06-14
KR900701261A (ko) 1990-12-01
DK177690A (da) 1990-09-13
DK175587B1 (da) 2004-12-13
JPH06102622B2 (ja) 1994-12-14
US5436272A (en) 1995-07-25
DE19975039I2 (de) 2000-03-30
LU90866I2 (fr) 2002-02-18
NL300066I2 (nl) 2002-06-03
NL300066I1 (nl) 2001-12-01
CA2003524C (en) 1999-10-19
IE61928B1 (en) 1994-11-30

Similar Documents

Publication Publication Date Title
ZA899058B (en) Treatment of obesity
EP0350279A3 (en) Treatment of water
GB2223959B (en) Treatment of nitrophenolic by-products
GB2219503B (en) Treatment of arthritis
AR243138A1 (es) Procedimiento para el tratamiento de un efluente acuoso.
GB8809205D0 (en) Treatment of oedema
GB8810748D0 (en) Novel treatment
GB2220652B (en) Treatment of pastures
GB8828679D0 (en) Novel treatment
GB8816505D0 (en) Novel treatment
GB8826819D0 (en) Treatment of sewage
GB8827043D0 (en) Treatment of materials
ZA899215B (en) Treatment of water
ZA897787B (en) Treatment of grain
GB8805885D0 (en) Treatment of onions
IE880666L (en) Compounds and treatment
GB8806481D0 (en) Treatment of ulcers
GB8816506D0 (en) Novel treatment
GB8826569D0 (en) Novel treatment
GB8819576D0 (en) Novel treatment
GB8801687D0 (en) Novel treatment
GB8810051D0 (en) Novel treatment
GB8820102D0 (en) Novel treatment
IE880120L (en) Novel treatment
GB8814811D0 (en) Novel treatment